SCHEMBL2960285

SCHEMBL2960285

CCOc1ccc(C2CCCCC2)cc1-c1csc(NC(=O)NN2CCN(CC(=O)N3CCOCC3)CC2)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.40
SMN1; SMN2 Q16637 6/20 0.40
MAPK1 P28482 5/20 0.40
HPGD P15428 5/20 0.40
MAPT P10636 4/20 0.40
NPC1 O15118 3/20 0.40
NPSR1 Q6W5P4 1/20 0.40
LMNA P02545 2/20 0.40
GAA P10253 2/20 0.40
KDM4E B2RXH2 2/20 0.40
PTBP1 P26599 1/20 0.40
HTT P42858 1/20 0.40
POLB P06746 1/20 0.38
TMEM97 Q5BJF2 8/20 0.38
SIGMAR1 Q99720 3/20 0.38
ABL1 P00519 1/20 0.37
USP2 O75604 2/20 0.37
TSHR P16473 1/20 0.37
HSD17B10 Q99714 1/20 0.37
MEN1 O00255 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2959063 0.94 NPC1 (0.41) ALDH1A1SMN1; SMN2HPGDMAPTNPC1
SCHEMBL2960057 0.93 MAPT (0.44) ALDH1A1SMN1; SMN2MAPK1HPGDMAPT
SCHEMBL2957660 0.87 CPT1A (0.41) ALDH1A1SMN1; SMN2MAPK1HPGDMAPT
SCHEMBL2957792 0.81 ACHE (0.43) ALDH1A1SMN1; SMN2MAPK1HPGDMAPT
SCHEMBL13198993 0.79 MAPT (0.45) ALDH1A1SMN1; SMN2MAPK1HPGDMAPT
SCHEMBL13199002 0.79 MAPT (0.45) ALDH1A1SMN1; SMN2MAPK1HPGDMAPT
SCHEMBL13198971 0.77 MAPT (0.42) ALDH1A1SMN1; SMN2MAPK1HPGDMAPT
SCHEMBL2948289 0.76 TLR9 (0.42) ALDH1A1SMN1; SMN2MAPK1HPGDMAPT
SCHEMBL2953795 0.75 KMT2A (0.39) ALDH1A1SMN1; SMN2MAPK1HPGDMAPT
SCHEMBL2953799 0.75 KMT2A (0.39) ALDH1A1SMN1; SMN2MAPK1HPGDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7767681-B2 2-Carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof SANOFI-AVENTIS (FR) 2010-08-03 US claimed
EP-1771425-B1 2-CARBAMIDE-4-PHENYLTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2008-05-14 EP claimed
US-20070179126-A1 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof SANOFI-AVENTIS (FR) 2007-08-02 US claimed
EP-1771425-A1 2-CARBAMIDE-4-PHENYLTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2007-04-11 EP claimed
WO-2006016039-A1 2-CARBAMIDE-4-PHENYLTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2006-02-16 WO claimed
US-7767681-B2 2-Carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof SANOFI-AVENTIS (FR) 2010-08-03 US disclosed
EP-1771425-B1 2-CARBAMIDE-4-PHENYLTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2008-05-14 EP disclosed
US-20070179126-A1 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof SANOFI-AVENTIS (FR) 2007-08-02 US disclosed
EP-1771425-A1 2-CARBAMIDE-4-PHENYLTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2007-04-11 EP disclosed
WO-2006016039-A1 2-CARBAMIDE-4-PHENYLTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2006-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070179126-A1 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof UGT2B7, PKD2, CYP2C19 ALDH1A1 1008/4885SMN1; SMN2 868/4885MAPK1 3794/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.